OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
Search results
221 results
-
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Awaiting development [GID-HST10019] Expected publication date: TBC
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Awaiting development [GID-HST10032] Expected publication date: TBC
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Awaiting development [GID-HST10046] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.
-
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 17 June 2022.
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Awaiting development [GID-TA10239] Expected publication date: TBC
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
Awaiting development [GID-TA10655] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Awaiting development [GID-TA10336] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Awaiting development [GID-TA10346] Expected publication date: TBC
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Awaiting development [GID-TA10453] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Awaiting development [GID-TA10777] Expected publication date: TBC
-
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940
Awaiting development [GID-TA10830] Expected publication date: TBC
-
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943
Awaiting development [GID-TA10831] Expected publication date: TBC
-
Mavorixafor for treating WHIM syndrome ID3946
Awaiting development [GID-TA10833] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Awaiting development [GID-TA10752] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Awaiting development [GID-TA10298] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Awaiting development [GID-TA10758] Expected publication date: TBC
-
Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]
Awaiting development [GID-TA10855] Expected publication date: TBC
-
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]
Awaiting development [GID-TA10889] Expected publication date: 14 September 2022
-
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Awaiting development [GID-TA10909] Expected publication date: TBC
-
Test347
Awaiting development [GID-TA10949] Expected publication date: TBC
-
Fezolinetant for menopause-related vasomotor symptoms [ID5071]
Awaiting development [GID-TA10953] Expected publication date: TBC
-
Canakinumab for untreated Schnitzler syndrome [ID4063]
Awaiting development [GID-TA10952] Expected publication date: TBC
-
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Awaiting development [GID-TA10957] Expected publication date: TBC
-
Vutrisiran for hereditary transthyretin amyloidosis [ID5074]
Awaiting development [GID-TA10954] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Awaiting development [GID-TA10750] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Awaiting development [GID-TA10681] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Awaiting development [GID-TA10306] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Awaiting development [GID-TA10426] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Awaiting development [GID-TA10393] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Awaiting development [GID-TA10439] Expected publication date: TBC
-
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Awaiting development [GID-TA10861] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Awaiting development [GID-TA10795] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development [GID-TA10716] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Awaiting development [GID-TA10843] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Awaiting development [GID-TA10848] Expected publication date: TBC